China News Service, Shenzhen, February 18 (Zhu Zuying) Shenzhen Hospital of the University of Hong Kong announced on the 18th that on the eve of the Spring Festival of the Year of the Tiger, Mr. Wei, a 26-year-old Hong Kong resident, suffered from a rare blood tumor and was quarantined in Shenzhen for 21 days. He was treated with CAR-T (Chimeric Antigen Receptor T cell therapy) at the University of Hong Kong Shenzhen Hospital and successfully defeated primary mediastinal large B-cell lymphoma.

  It is reported that the CAR-T drug used by Mr. Wei will be listed on the mainland in June 2021. He was transferred to the Department of Hematology, University of Hong Kong, Shenzhen Hospital through the Queen Mary Hospital of Hong Kong and received CAR-T treatment. The drug Pola monoclonal antibody introduced overseas was used as bridging therapy, and after CAR-T infusion, he recovered and was discharged from hospital and returned to Hong Kong smoothly.

  At first, Mr. Wei only had repeated fever and cough. He went to the community clinic for examination and thought it was just a common cold. After 2 months, he still did not get better. After checking the blood oxygen, he found that it was far below the normal range, so he went to the hospital under the doctor's advice. Take a chest X-ray.

  "When I saw the results of the chest X-ray with pale lungs, I thought it was pneumonia or tuberculosis. After a series of blood tests and CT examinations, I was diagnosed with a blood tumor disease, and I was very disappointed." Mr. Wei said.

  Mr. Wei's attending doctor at Queen Mary Hospital, Shen Peiyan, said that Mr. Wei had undergone first-line high-dose chemotherapy, but his condition did not improve after the tumor shrunk briefly.

"In June 2021, he was diagnosed with lymphoma central involvement. After radiotherapy and second-line chemotherapy, the evaluation was still ineffective. The situation is not optimistic."

  According to reports, among hematological tumor diseases, primary mediastinal large B-cell lymphoma is relatively rare, and most patients are sensitive to chemotherapy. It is very rare for Mr. Wei to be insensitive to chemotherapy and to quickly transfer to the center.

  After conducting a multidisciplinary consultation to comprehensively evaluate the patient's condition, Professor Kwong Wolin, head of the Department of Internal Medicine at Queen Mary Hospital, and his team proposed a new treatment plan - CAR-T therapy.

CAR-T therapy is a method of killing cancer cells in the body by genetically modifying the patient's own T cells (a type of immune cells in the human body).

  Since the CAR-T drugs currently listed in Hong Kong do not have indications for Mr. Wei, Kwong Wolin quickly contacted Zhu Zhimei, director of the Department of Hematology at the University of Hong Kong Shenzhen Hospital, informed Mr. Wei of his condition, and quickly transferred Mr. Wei to the University of Hong Kong Shenzhen Hospital.

  Zhu Zhimei said: "Before this, the hospital's hematology department had been preparing for the introduction of CAR-T for two years. When CAR-T was launched in the mainland, the hospital quickly completed the admission work."

  Afterwards, Mr. Wei and his family went to Shenzhen. On November 2, 2021, he went to the Department of Hematology, University of Hong Kong, Shenzhen Hospital for treatment; on December 7, 2021, Mr. Wei received a 30-minute one-time infusion, millions of autoantibodies. Cancer CAR-T cells returned to Mr. Wei's body.

  There is a complication rate of as high as 80% to 90% after CAR-T treatment. With the efforts of the hospital team, Mr. Wei did not experience any serious adverse complications within 22 days after the infusion.

His physical condition gradually improved and he was discharged from the hospital on December 29, 2021.

  It is understood that the Shenzhen Hospital of the University of Hong Kong has introduced the first drug "anti-D immune globulin injection" and the first medical device "magnetic controllable extension titanium rod" since it was approved as a designated pilot hospital for the "Hong Kong-Macao Medicine and Machinery" policy. A total of 13 medicines and 3 devices have been used, and more than 360 patients have enjoyed benefits.

(over)